Prognostic factors for refractory outcome in localizing TIO: experience in a tertiary center.

J Clin Endocrinol Metab

Division of Endocrinology and Metabolism, Department of Medicine, Mayo Clinic Rochester, USA.

Published: January 2025

Context: TIO, a paraneoplastic disorder characterised by renal phosphate wasting, is cured by surgical removal of the culprit tumour. Despite correct localization, some remain refractory to intervention, resulting in substantial long-term medical complications.

Aim: We aim to identify risk factors associated with a refractory outcome.

Methods: This is a retrospective cohort of 44 TIO patients diagnosed from 1998-2023 who underwent targeted intervention following successfully localization. Cure was defined as maintenance of normophosphatemia without supplementation for >1 month, maintained at last follow-up.

Results: 29 patients achieved cure and 15 had a refractory outcome. On univariate cox regression, HR for predicting cure was 3.43 (95%CI 1.45-8.11, p=0.005) for patients diagnosed after 2013 (compared to before), and that for a negative surgical tumor margin was 2.56 (95%CI 1.20-5.45, p=0.015) compared to positive/unspecified margins. After adjustment for year of diagnosis, tumors originating from soft tissue (HR 2.72 versus bone, 95%CI 1.22-6.09, p=0.015) or located outside the spine (HR 0.22 for spine versus non-spine, 95%CI 0.05-0.96, p=0.043) had higher chances of cure. Size of tumor, age, gender, or baseline biochemistry including levels of FGF23, phosphorus, 1,25(OH)2D or ALP were not predictive of cure. Post-procedural FGF23 was the best biochemical marker of cure (AUC 0.899, 95%CI 0.764-1.00, p < 0.001).

Conclusion: Tumors diagnosed within the past decade with clear resection margins had more favorable prognoses. With regards to tumoral factors, baseline biochemistry was uninformative in predicting cure, while bone and/or spine localizations were associated with a refractory outcome.

Download full-text PDF

Source
http://dx.doi.org/10.1210/clinem/dgae911DOI Listing

Publication Analysis

Top Keywords

refractory outcome
12
associated refractory
8
patients diagnosed
8
predicting cure
8
baseline biochemistry
8
cure
7
refractory
5
95%ci
5
prognostic factors
4
factors refractory
4

Similar Publications

Background: Posterior nasal nerve (PNN) cryoablation improves chronic rhinitis (CR) symptoms in 70-80% of cases, including clear thin rhinorrhea (CTR). This study's purpose was to determine time to and degree of CTR recurrence following cryoablation.

Methods: A multicenter retrospective cohort study was conducted on patients who underwent PNN cryoablation to treat CR-related CTR refractory to ipratropium bromide nasal spray (IBNS).

View Article and Find Full Text PDF

Objective: Extracorporeal membrane oxygenation (ECMO) is among the most resource-intensive therapies in critical care. The COVID-19 pandemic highlighted the lack of ECMO resource allocation tools. We aimed to develop a continuous ECMO risk prediction model to enhance patient triage and resource allocation.

View Article and Find Full Text PDF

Background: Clinical studies have demonstrated the high efficacy of using chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) and orphan G protein-coupled receptor, class C group 5 member D (GPRC5D) to treat relapsed or refractory multiple myeloma (RRMM). In this study, we compared the efficacy and safety of BCMA CAR-T-cell therapy (BCMA CAR-T) and GPRC5D CAR T-cell therapy (GPRC5D CAR-T) in patients with RRMM.

Methods: We retrieved and included eligible clinical trials of BCMA or GPRC5D CAR-T for RRMM patients.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) that is relapsed and/or refractory post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. In a prior study, we demonstrated that AML relapse in high-risk patients was prevented by post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8 T cells engineered to express a high-affinity Wilms Tumor Antigen 1 (WT1)-specific T-cell receptor (TTCR- C4). However, in the present study, infusion of EBV- or Cytomegalovirus (CMV)-specific T did not clearly improve outcomes in fifteen patients with active disease post-HCT.

View Article and Find Full Text PDF

FLT3 mutations are among the most common genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis. Significant advancements have been made in developing FLT3 inhibitors (FLT3Is), such as quizartinib, which have improved treatment outcomes in both newly diagnosed and relapsed/refractory AML. Resistance to FLT3Is remains a major clinical challenge, driven by diverse mechanisms including FLT3 point mutations, cellular escape pathways, and the influence of the bone marrow microenvironment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!